Person: GÜL, CUMA BÜLENT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜL
First Name
CUMA BÜLENT
Name
9 results
Search Results
Now showing 1 - 9 of 9
Publication Association of morning blood pressure surge (mbps) with left ventricular hypertrophy in autosomal dominant polycystic kidney disease (ADPKD): Across sectional study(Oxford Univ Press, 2016-05-01) Sağ, Saim; Yıldız, Abdulmecit; Ersoy, Alparslan; Ocakoğlu, Gökhan; Oruç, Ayşegül; Güngören, Fatih; Ayar, Yavuz; Gül, Cuma Bülent; Güllülü, Sümeyye; Güllülü, Mustafa; Sağ, Saim; YILDIZ, ABDULMECİT; ERSOY, ALPARSLAN; OCAKOĞLU, GÖKHAN; ORUÇ, AYŞEGÜL; Güngören, Fatih; Ayar, Yavuz; GÜL, CUMA BÜLENT; GÜLLÜLÜ, NAZMİYE SÜMEYYE; GÜLLÜLÜ, MUSTAFA; Uludağ Üniversitesi/Tıp Fakültesi/Kardioloji Bölümü; 0000-0002-1114-6051; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0003-2467-9356; AAH-5180-2021; AGF-0767-2022; AAW-9185-2020; AAH-5054-2021; O-9948-2015; AAA-3163-2021; HLG-6346-2023; AAH-4002-2021; A-7063-2018; GSE-0029-2022; HIG-9032-2022; JGR-6552-2023; CTG-8811-2022Publication Irritable bowel syndrome in patients on renal replacement treatment(Oxford Univ Press, 2015-05-01) Aktaş, Nimet; Oruç, Ayşegül; Ersoy, Alparslan; Coşkun, Belkıs Nihan; Gül, Bülent; Yıldız, Abdulmecit; Ayar, Yavuz; Sayılar, Emel Işıktaş; Aktaş, Nimet; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; COŞKUN, BELKIS NİHAN; GÜL, CUMA BÜLENT; YILDIZ, ABDULMECİT; Ayar, Yavuz; Sayılar, Emel Işıktaş; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0002-0710-0923; 0000-0003-0298-4157; AGF-0767-2022; AAH-4002-2021; AAH-5054-2021; O-9948-2015; AAG-7155-2021; GSE-0029-2022; W-2575-2017Publication Analysis of risk factors associated with urinary tract infection in renal transplant recipients(Oxford University Press, 2015-05-01) Ersoy, Alparslan; Aktaş, Nimet; Oruç, Ayşegül; Gül, Bülent; Yıldız, Abdülmecit; Sayılar, Emel Işıktaş; Ayar, Yavuz; Akalın, Halis; ERSOY, ALPARSLAN; ORUÇ, AYŞEGÜL; GÜL, CUMA BÜLENT; YILDIZ, ABDULMECİT; AKALIN, EMİN HALİS; AKTAŞ, NİMET; SAYILAR, EMEL IŞIKTAŞ; AYAR, YAVUZ; 0000-0002-0342-9692; 0000-0003-4607-9220; 0000-0001-7530-1279; AAH-5054-2021; AAH-4002-2021; W-2575-2017; AAU-8952-2020; GSE-0029-2022; O-9948-2015; AGF-0767-2022Publication Effects of anti-tumor necrosis factor therapy on kidney function in patients with inflammatory arthritis(Oxford Univ Press, 2013-05-01) Öztürk, Oğuzhan; Yıldız, Abdulmecit; Gül, Cuma Bülent; Dilek, Kamil; GÜL, CUMA BÜLENT; DİLEK, KAMİL; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0003-2467-9356; A-7063-2018; EUF-5229-2022Publication Increased FGF23 and decreased arterial compliance in early autosomal dominant polycystic kidney disease(Oxford Univ Press, 2013-05-01) Gül, Bülent; Çekiç, Selime; Asiltaş, Burak; Doğan, Selda; Aktaş, Nimet; Oruç, Ayşegül; Doğan, İbrahim; Ersoy, Alparslan; Güllülü, Mustafa; Yurtkuran, Mustafa; Yıldız, Abdülmecit; GÜL, CUMA BÜLENT; Çekiç, Selime; Asiltaş, Burak; Doğan, Selda; Aktaş, Nimet; ORUÇ, AYŞEGÜL; ERSOY, ALPARSLAN; GÜLLÜLÜ, MUSTAFA; Yurtkuran, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-2589-8585; 0000-0002-0342-9692; AAH-5054-2021; AAH-4002-2021; I-7575-2015; JRG-6380-2023; CHU-7675-2022; EKV-7386-2022; CCH-7205-2022; CSP-3307-2022; EGT-2006-2022Publication Analysis of liver function test abnormalities in kidney transplant recipients(Oxford Univ Press, 2015-05-01) Dizdar, Oğuzhan Sıtkı; Ersoy, Alparslan; Yıldız, Abdulmecit; Ayar, Yavuz; Oruç, Ayşegül; Gül, Cuma Bülent; Dizdar, Oğuzhan Sıtkı; ERSOY, ALPARSLAN; YILDIZ, ABDULMECİT; Ayar, Yavuz; ORUÇ, AYŞEGÜL; GÜL, CUMA BÜLENT; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Bölümü; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Bölümü; 0000-0002-4066-929X; 0000-0003-4607-9220; 0000-0002-0342-9692; 0000-0003-2467-9356; O-9948-2015; D-6213-2013; AAH-4002-2021; AGF-0767-2022; AAH-5054-2021; GSE-0029-2022; A-7063-2018Publication Morning blood pressure surge in early autosomal dominant polycystic kidney disease and its relation with left ventricular hypertrophy(Taylor & Francis Ltd, 2021-01-01) Yıldız, Abdülmecit; Sağ, Saim; Gül, Cuma Bülent; Güllülü, Sümeyye; Can, Fatma Ezgi; Bedir, Ömer; Aydın, Mehmet Fethullah; Oruç, Ayşegül; Demirel, Sadettin; Akgür, Suat; Güllülü, Mustafa; Ersoy, Alparslan; YILDIZ, ABDULMECİT; Sağ, Saim; GÜL, CUMA BÜLENT; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Can, Fatma Ezgi; Bedir, Ömer; Aydın, Mehmet Fethullah; ORUÇ, AYŞEGÜL; DEMİREL, SADETTİN; AKGÜR, SUAT; GÜLLÜLÜ, MUSTAFA; ERSOY, ALPARSLAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Anabilim Dalı.; 0000-0002-5665-7402; 0000-0002-0342-9692; HIG-9032-2022; AAW-9185-2020; JGR-6552-2023; JSL-7718-2023; IVE-3975-2023; AAJ-8220-2020; AAH-4002-2021; AAH-3460-2021; EJA-1761-2022; JGS-9425-2023; AAH-5054-2021Introduction: The activation of the sympathetic nervous system, which usually leads to a swift surge in blood pressure in the morning hours (MBPS) may be the cause of left ventricular hypertrophy (LVH) and endothelial dysfunction (ED) in early autosomal dominant polycystic kidney disease (ADPKD) patients. We studied the association between MBPS and LVH in ADPKD patients with preserved renal functions.Methods: Patients with ADPKD with preserved renal functions were enrolled. Prewaking MBPS was calculated using ambulatory blood pressure monitoring. The patients were categorized as MBPS (>= median) and non-MBPS (Publication Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey(Kare Yayınevi, 2017-07-01) Sağ, Saim; Kaderli, Aysel Aydın; Yıldız, Abdülmecit; Gül, Bülent Cuma; Özdemir, Bülent; Baran, İbrahim; Güllülü, Sümeyye; Aydınlar, Ali; Çavuşoğlu, Yüksel; Sağ, Saim; Kaderli, Aysel Aydın; YILDIZ, ABDULMECİT; GÜL, CUMA BÜLENT; ÖZDEMİR, BÜLENT; Baran, İbrahim; GÜLLÜLÜ, NAZMİYE SÜMEYYE; AYDINLAR, ALİ; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; AAI-6632-2021; AAW-9185-2020; A-7063-2018; CXL-7581-2022; HIG-9032-2022; JHE-3353-2023; CDA-1396-2022; JGR-6552-2023Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration <= 125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety.Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p<0.0001, p=0.037, p<0.0001, and p<0.0001, respectively), whereas furosemide dosage, body weight, heart rate, systolic and diastolic blood pressure, and New York Heart Association class decreased significantly in response to tolvaptan treatment, without a rise in serum creatinine or urea concentrations (p<0.0001, p<0.0001, p=0.001, p<0.049, p<0.009 ve p=0.001, respectively).Conclusion: In this retrospective, single-centered study conducted in a small group of Turkish patients, short-term treatment with low-dose tolvaptan added to standard therapy of hypervolemic HF patients with severe hyponatremia was well tolerated with a low rate of major side effects and was effective in correcting severe hyponatremia.Publication Relationship between fetuin-a level and cardiovascular risk factors in peritoneal dialysis patients(Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2013-01-01) Çubukçuoğlu, Tarık; Rasschaert, Nele; Kaçan, Turgut; Gül, Cuma Bülent; Yavuz, Mahmut; Çubukçuoğlu, Tarık; GÜL, CUMA BÜLENT; YAVUZ, MAHMUT; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Bilim Dalı.; 0000-0003-2467-9356; A-7063-2018; ESA-7356-2022; EHM-7377-2022OBJECTIVE: Vascular calcifications and chronic inflammation are the main reasons of the decreased life span and prevalent morbidity for patients on renal replacement therapy due to chronic renal failure. Scoring systems used to determine the chance of cardiovascular (CV) risk and traditional CV risk factors frequently fail to identify the risk in these patients. New markers to predict the risk of CV disease continues to be investigated. One of the most studied marker in recent years is a serum glycoprotein fetuin-A, which is major calcification inhibitor. We aimed to study the relation between fetuin-A subclinical inflammation and cardiovascular risk factors in Peritoneal Dialysis (PD) patients and healthy volunteers.MATERIAL and METHODS: Forty-eight PD patients and 27 healthy volunteers were included in the study. Fetuin-A levels, body weight, body mass index, blood pressure, markers of inflammation (sedimentation, C-reactive protein, ferritin) and lipid profile tests were performed. The relationship between these parameters was compared with fetuin-A.RESULTS : CRP and sedimentation levels were significantly higher in the group of PD patients. Fetuin-A levels were significantly lower in PD patients than the control group. There was a negative correlation between serum fetuin-A levels, average arterial blood pressure and CRP.CONCLUSION: Fetuin-A can be used to predict subclinic inflammation, and cardiovascular mortality risk in PD patients.